特写独家！优然牧业(09858)迎来领导层变动：袁军获委任为董事会主席

优然牧业(09858)迎来领导层变动：袁军获委任为董事会主席

香港 - 2024年6月18日 - 优然牧业(09858)今日宣布，公司董事会已于2024年6月14日作出决议，委任袁军先生为公司董事会主席，自当日起生效。

袁军先生现任优然牧业执行董事兼总裁，拥有超过15年的乳制品行业从业经验。他于2009年加入优然牧业，历任多个高级管理职位，在公司战略发展、运营管理等方面做出了卓越贡献。在他的领导下，优然牧业业务取得长足发展，盈利能力持续增强，公司在业内影响力不断提升。

袁军先生获委任为董事会主席，标志着优然牧业进入新的发展阶段。业界人士普遍认为，袁先生拥有丰富的行业经验和卓越的领导能力，能够带领公司继续前进，创造更大的价值。

新任主席袁军先生履历简介

袁军先生毕业于清华大学，拥有工商管理硕士学位。他曾在多家知名企业担任高级管理职务，积累了丰富的管理经验。加入优然牧业之前，他曾任职于蒙牛乳业、伊利股份等公司。

袁先生是一位充满活力和远见的领导者，他对乳制品行业有着深刻的洞察力和独到的见解。他致力于将优然牧业打造成全球领先的乳制品企业，为中国乃至世界消费者提供高品质的乳制品产品。

优然牧业(09858)简介

优然牧业是一家领先的乳制品企业，主要从事液态奶、奶粉、乳酸饮料等产品的生产和销售。公司拥有多个现代化生产基地和强大的研发团队，产品远销国内外市场。

优然牧业始终坚持以消费者为中心，致力于为消费者提供安全、健康、美味的乳制品产品。公司先后获得“中国名牌”、“国家级绿色食品”、“中国驰名商标”等多项荣誉。

展望未来

在袁军先生的带领下，优然牧业将继续坚持创新驱动发展战略，不断提升产品质量和服务水平，努力为股东和投资者创造更大价值。公司将立志成为全球最值得信赖的乳制品企业，为中国乃至世界消费者带来更加健康、美好的生活。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.